Stan­ford spin­out Forty Sev­en ar­rives at AS­CO with a snap­shot of promis­ing CD47 da­ta — and a $115M IPO in hand

CHICA­GO — Here’s a neat trick for up-and-com­ing on­col­o­gy biotechs to con­sid­er.

Ex­ecs for Forty Sev­en, the CD47 star found­ed by Stan­ford’s leg­endary Irv Weiss­man, filed for a $115 mil­lion IPO on Fri­day and then — in­stead of hun­ker­ing down for the qui­et pe­ri­od — prompt­ly flew out to Chica­go to tout a promis­ing set of proof-of-con­cept da­ta for their lead drug at AS­CO.

Forty Sev­en has pre­lim­i­nary da­ta on 22 pa­tients tak­ing 5F9, with an im­pres­sive ini­tial snap­shot of ear­ly da­ta for the small group. Fif­teen of the pa­tients suf­fer from treat­ment re­sis­tant dif­fuse large B-cell lym­phoma (DL­B­CL) and the oth­er 7 have fol­lic­u­lar lym­phoma. In DL­B­CL in­ves­ti­ga­tors tracked an ob­jec­tive re­sponse rate of 40% with a third achiev­ing a com­plete re­sponse; in fol­lic­u­lar lym­phoma the ORR was 71% with 43% achiev­ing a CR.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER